June 7, 2017, New York City

 
 

Richard Craib
Founder & CEO, Numerai

Richard Craib teaches machines to trade in the stock market. At the helm of Numerai, the young founder has devoted the fledging hedge fund to his two core areas of interest: pure mathematics and data science. In practice, Craib’s fund works less like an automated army of quants and more like a collaborative AI research project; while machines make the trades, Numerai’s sprawling community of anonymous data scientists compete to create the best trading algorithm. (He even created his own crypto-currency, dubbed the Numeraire, to compensate the most prolific contributors.) His ultimate goal for both Numerai and the Numeraire is to introduce more of an open source approach to Wall Street. Before he was teaching machines the ins and outs of investing, Craib was a data scientist at an asset management firm with $15 billion under management.


Jennifer A. Doudna, Ph.D
Technology Co-Inventor, CRISPR- Cas9

Dr. Jennifer Doudna is redefining what’s possible with genetic engineering. As an internationally renowned professor of Chemistry and Molecular and Cell Biology at U.C. Berkeley, Doudna and her colleagues rocked the research world in 2012 by uncovering a simple way of editing the DNA of any organism using a common protein found in bacteria. Doudna’s novel approach of having proteins proactively ‘snip’ DNA into new sequences has opened the floodgates of possibility for non-human and human applications including assisting researchers in the fight against HIV, sickle cell anemia and cystic fibrosis. Today Doudna is widely recognized as a leading expert on RNA-protein biochemistry, CRISPR biology, and genome engineering, and currently holds memberships with the Howard Hughes Medical Institute, and Lawrence Berkeley National Lab, along with the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors and the American Academy of Arts and Sciences.


Jim McCarthy
EVP, Innovation & Strategic Partnerships, Visa Inc.  

Jim McCarthy’s experience lies at the intersection of commerce and innovation. As Visa’s executive vice president of Innovation & Strategic Partnerships, McCarthy is responsible for developing the company’s innovation efforts. Under his leadership, consumers and merchants alike now have the Visa Token Service, a new security technology that has become the standard for payment security and fraud prevention in mobile payments. Jim oversees Visa’s open platform program, Visa Developer, which offers access to  Visa products and services via readily consumable APIs in an effort to enable speed to market and enhance overall client experiences. Earlier in his Visa tenure, McCarthy was Head of Emerging Products for Visa USA, where he drove the coordination, deployment and management of emerging products and payment services. Prior to joining Visa in 1999, McCarthy worked at IBM where he served as the senior client representative to Bank of America


Lily Peng
Product Manager, Google Brain

Dr. Lily Peng is one of the many minds working to apply Google Brain to medicine. She is part of a special group of researchers focused solely on medical applications for AI. She says her goal isn’t to replace doctors, but to build a system that will help overworked physicians in the developing world examine many more patients over the course of a day. “We want to increase access to care everywhere,” says Peng, who imagines a future where doctors work alongside AI to examine medical images to detect all sorts of ailments. Prior to Google, Peng cofounded Nano Precision Medical, a startup focused on developing tiny implantable capsules that automatically dispense life-saving medicines to patients.